Patents by Inventor Kevin J. Hodgetts
Kevin J. Hodgetts has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20210363154Abstract: The present invention relates to 2-amino-4-arylpyrimidine and 2-amino-4-aryltriazine compounds as inhibitors of heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of a disorder hi a subject. For example, the disorder is a neurodegenerative disease.Type: ApplicationFiled: March 29, 2021Publication date: November 25, 2021Inventors: Gregory D. CUNY, Marcie A. GLICKSMAN, Steven L. MATHIEU, Yukari Y. PERRELLA, Vincent DARMENCY, Hrvoje LUSIC, Kevin J. HODGETTS
-
Patent number: 10961254Abstract: The present invention relates to 2-amino-4-arylpyrimidine and 2-amino-4-aryltriazine compounds as inhibitors of heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of a disorder in a subject. For example, the disorder is a neurodegenerative disease.Type: GrantFiled: July 1, 2019Date of Patent: March 30, 2021Assignees: Yuma Therapeutics, Inc., The Brigham and Women's Hospital, Inc.Inventors: Gregory D. Cuny, Marcie A. Glicksman, Kevin J. Hodgetts, Steven L. Mathieu, Yukari Y. Perrella, Vincent Darmency, Hrvoje Lusic
-
Publication number: 20190389878Abstract: The present invention relates to 2-amino-4-arylpyrimidine and 2-amino-4-aryltriazine compounds as inhibitors of heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of a disorder in a subject. For example, the disorder is a neurodegenerative disease.Type: ApplicationFiled: July 1, 2019Publication date: December 26, 2019Inventors: Gregory D. CUNY, Marcie A. GLICKSMAN, Kevin J. HODGETTS, Steven L. MATHIEU, Yukari Y. PERRELLA, Vincent DARMENCY, Hrvoje LUSIC
-
Patent number: 10336768Abstract: The present invention relates to 2-amino-4-arylpyrimidine and 2-amino-4-aryltriazine compounds as inhibitors of heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of a disorder in a subject. For example, the disorder is a neurodegenerative disease.Type: GrantFiled: June 15, 2015Date of Patent: July 2, 2019Assignees: Yuma Therapeutics, Inc., The Brigham and Women's Hospital, Inc.Inventors: Gregory D. Cuny, Marcie A. Glicksman, Kevin J. Hodgetts, Steven L. Mathieu, Yukari Y. Perrella, Vincent Darmency, Hrvoje Lusic
-
Publication number: 20170217923Abstract: Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP) are described herein. Exemplary disorders include schizophrenia and cognitive deficit.Type: ApplicationFiled: March 13, 2017Publication date: August 3, 2017Inventors: Masaki Suzuki, Kazumi Kondo, Muneaki Kurimura, Krishna Reddy Valluru, Akira Takahashi, Takeshi Kuroda, Haruka Takahashi, Tae Fukushima, Shin Miyamura, Indranath Ghosh, Abhishek Dogra, Geraldine Harriman, Amy Elder, Satoshi Shimizu, Kevin J. Hodgetts, Jason S. Newcom
-
Patent number: 9630947Abstract: Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP), such as those of formula (III), and composition thereof are described herein. Exemplary disorders include schizophrenia and cognitive deficit.Type: GrantFiled: April 21, 2015Date of Patent: April 25, 2017Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Masaki Suzuki, Kazumi Kondo, Muneaki Kurimura, Krishna Reddy Valluru, Akira Takahashi, Takeshi Kuroda, Haruka Takahashi, Tae Fukushima, Shin Miyamura, Indranath Ghosh, Abhishek Dogra, Geraldine Harriman, Amy Elder, Satoshi Shimizu, Kevin J. Hodgetts, Jason S. Newcom
-
Publication number: 20170107228Abstract: The present invention relates to 2-amino-4-arylpyrimidine and 2-amino-4-aryltriazine compounds as inhibitors of heat shock protein 90 family of chaperone proteins. The invention also features pharmaceutical compositions and kits that include the compounds and compositions of the invention. The invention further relates to the medical use of these compounds and compositions for the treatment of a disorder in a subject. For example, the disorder is a neurodegenerative disease.Type: ApplicationFiled: June 15, 2015Publication date: April 20, 2017Inventors: Gregory D. CUNY, Marcie A. GLICKSMAN, Kevin J. HODGETTS, Steven L. MATHIEU, Yukari Y. PERRELLA, Vincent DARMENCY, Hrvoje LUSIC
-
Publication number: 20150307477Abstract: Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP) are described herein. Exemplary disorders include schizophrenia and cognitive deficit.Type: ApplicationFiled: April 21, 2015Publication date: October 29, 2015Inventors: Masaki Suzuki, Kazumi Kondo, Muneaki Kurimura, Krishna Reddy Valluru, Akira Takahashi, Takeshi Kuroda, Haruka Takahashi, Tae Fukushima, Shin Miyamura, Indranath Ghosh, Abhishek Dogra, Geraldine Harriman, Amy Elder, Satoshi Shimizu, Kevin J. Hodgetts, Jason S. Newcom
-
Patent number: 9133204Abstract: 5-Membered heterocyclic amides and related compounds are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: GrantFiled: September 9, 2014Date of Patent: September 15, 2015Assignee: H. Lundbeck A/SInventors: Hongbin Li, Jun Yuan, Rajagopal Bakthavatchalam, Kevin J Hodgetts, Qin Guo, Scott M. Capitosti, Jianmin Mao, David J. Wustrow
-
Patent number: 9073890Abstract: Compounds, pharmaceutical compositions containing the compounds, and methods of using the compounds to treat a disorder, e.g., schizophrenia and cognitive deficit, in a subject are described herein. The compounds disclosed herein include quinoline and quinazoline-containing compounds that modulate striatal-enriched tyrosine phosphatase (STEP) activity.Type: GrantFiled: December 30, 2010Date of Patent: July 7, 2015Assignee: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Masaki Suzuki, Kazumi Kondo, Muneaki Kurimura, Krishna Reddy Valluru, Akira Takahashi, Takeshi Kuroda, Haruka Takahashi, Tae Fukushima, Shin Miyamura, Indranath Ghosh, Abhishek Dogra, Geraldine Harriman, Amy Elder, Satoshi Shimizu, Kevin J. Hodgetts, Jason S. Newcom
-
Publication number: 20150005293Abstract: 5-Membered heterocyclic amides and related compounds are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: ApplicationFiled: September 9, 2014Publication date: January 1, 2015Inventors: Hongbin Li, Jun Yuan, Rajagopal Bakthavatchalam, Kevin J. Hodgetts, Qin Guo, Scott M. Capitosti, Jianmin Mao, David J. Wustrow
-
Publication number: 20140315886Abstract: Methods of treating disorders using compounds (I) that modulate stri-atal-enriched tyrosine phosphatase (STEP) are described herein. Exemplary disorders include schizophrenia and cognitive deficit. Formula (I).Type: ApplicationFiled: June 28, 2012Publication date: October 23, 2014Applicant: OTSUKA PHARMACEUTICAL CO., LTD.Inventors: Masaki Suzuki, Kazumi Kondo, Muneaki Kurimura, Krishna Reddy Valluru, Akira Takahahi, Takeshi Kuroda, Haruka Takahashi, Tae Fukushima, Shin Miyamura, Indranath Ghosh, Abhishek Dogra, Geraldine Harriman, Amy Elder, Satoshi Shimiza, Kevin J. Hodgetts, Jason S. Newcom
-
Publication number: 20130053341Abstract: Methods of treating disorders using compounds that modulate striatal-enriched tyrosine phosphatase (STEP) are de-scribed herein. Exemplary disorders include schizophrenia and cognitive deficit.Type: ApplicationFiled: December 30, 2010Publication date: February 28, 2013Inventors: Masaki Suzuki, Kazumi Kondo, Muneaki Kurimura, Krishna Reddy Valluru, Akira Takahashi, Takeshi Kuroda, Haruka Takahashi, Tae Fukushima, Shin Miyamura, Indranath Ghosh, Abhishek Dogra, Geraldine Harriman, Amy Elder, Satoshi Shimizu, Kevin J. Hodgetts, Jason S. Newcom
-
Patent number: 7935702Abstract: Substituted biaryl quinolin-4-ylamine analogues of Formula I are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: GrantFiled: October 12, 2005Date of Patent: May 3, 2011Assignee: Neurogen CorporationInventors: Rajagopal Bakthavatchalam, Timothy M. Caldwell, Bertrand L. Chenard, Kevin J. Hodgetts, Scott Michael Capitosti
-
Publication number: 20100292236Abstract: 5-Membered heterocyclic amides and related compounds are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using such compounds to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: ApplicationFiled: July 21, 2008Publication date: November 18, 2010Applicant: H. LUNDBECK A/SInventors: Hongbin Li, Jun Yuan, Rajagopal Bakthavatchalam, Kevin J. Hodgetts, Scott M. Capitosti, Jianmin Mao, David J. Wustrow, Qin Guo
-
Publication number: 20090286767Abstract: Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: ApplicationFiled: February 9, 2009Publication date: November 19, 2009Applicant: Neurogen CorporationInventors: Rajagopal Bakthavatchalam, Timothy M. Caldwell, Bertrand L. Chenard, Stéphane De Lombaert, Kevin J. Hodgetts
-
Publication number: 20090082362Abstract: Disclosed are diaryl piperazines and related compounds. These compounds are selective modulators of capsaicin receptors, including human capsaicin receptors, that are, therefore, useful in the treatment of a chronic and acute pain conditions, itch and urinary incontinence. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds of the invention are also useful as probes for the localization of capsaicin receptors and as standards in assays for capsaicin receptor binding and capsaicin receptor mediated cation conductance. Methods of using the compounds in receptor localization studies are given.Type: ApplicationFiled: March 28, 2008Publication date: March 26, 2009Inventors: Rajagopal Bakthavatchalam, Alan Hutchison, Robert W. DeSimone, Kevin J. Hodgetts, James E. Krause, Geoffrey G. White
-
Patent number: 7488740Abstract: Substituted quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: GrantFiled: July 14, 2004Date of Patent: February 10, 2009Assignee: Neurogen CorporationInventors: Rajagopal Bakthavatchalam, Timothy M. Caldwell, Bertrand L. Chenard, Stéphane De Lombaert, Kevin J. Hodgetts
-
Patent number: 7432275Abstract: Acid-substituted quinazolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: GrantFiled: December 12, 2003Date of Patent: October 7, 2008Assignee: Neurogen CorporationInventors: Rajagopal Bakthavatchalam, Charles A. Blum, Harry Brielmann, Timothy M. Caldwell, Stéphane DeLombaert, Kevin J. Hodgetts, Xiaozhang Zheng
-
Publication number: 20080175794Abstract: Substituted pyridazinyl- and pyrimidinyl-quinolin-4-ylamine analogues are provided. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are particularly useful in the treatment of conditions associated with pathological receptor activation in humans, domesticated companion animals and livestock animals. Pharmaceutical compositions and methods for using them to treat such disorders are provided, as are methods for using such ligands for receptor localization studies.Type: ApplicationFiled: January 25, 2006Publication date: July 24, 2008Applicant: NEUROGEN CORPORATIONInventors: Timothy M. Caldwell, Bertrand L. Chenard, Kevin J. Hodgetts